Lysyl oxidase and hypoxia-inducible factor 1α: biomarkers of gastric cancer

Table 2 Relationship between lysyl oxidase and clinicopathological factors in patients with gastric cancer

Characteristics	Sample size, n	LOX		P
		Low expression (%)	High expression (%)
Gender		90 (64.3)	50 (35.7)
Male	112	73 (65.2)	39 (34.8)	0.659
Female	28	17 (60.7)	11 (39.3)
Age
< 60 yr	67	44 (65.7)	23 (34.3)	0.743
≥ 60 yr	73	46 (63.0)	27 (37.0)
Tumor location
Upper part	57	37 (64.9)	20 (35.1)	0.978
Middle part	34	21 (61.8)	13 (38.2)
Lower part	44	29 (65.9)	15 (34.1)
Total stomach	5	3 (60.0)	2 (40.0)
Tumor size
< 5 cm	57	39 (68.4)	18 (31.6)	0.397
≥ 5 cm	83	51 (61.4)	32 (38.6)
Depth of invasion
T1	5	5 (100.0)	0 (0.0)	0.005
T2	13	12 (92.3)	1 (7.7)
T3	85	56 (65.9)	29 (34.1)
T4	37	17 (45.9)	20 (54.1)
Lymphatic metastasis
0	34	33 (97.1)	1 (2.9)	0.000
1-2	32	24 (75.0)	8 (25.0)
3-6	31	21 (67.7)	10 (32.3)
7-15	37	12 (32.4)	25 (67.6)
≥ 16	6	0 (0.0)	6 (100.0)
Borrmann classification
Type I	16	12 (75.0)	4 (25.0)	0.340
Type II or III	110	67 (60.9)	43 (39.1)
Type IV	11	8 (72.7)	3 (27.3)
Type V	3	3 (100.0)	0 (0.0)
WHO histological classification
Adenocarcinoma	77	48 (62.3)	29 (37.7)	0.862
Signet-ring cell carcinoma	17	13 (76.5)	4 (23.5)
Mucinous adenocarcinoma	8	5 (62.5)	3 (37.5)
Mixed carcinoma	32	20 (62.5)	12 (37.5)
Neuroendocrine carcinoma	6	4 (66.7)	2 (33.3)
Lauren parting
Intestinal type	65	42 (64.6)	23 (35.4)	0.909
Diffuse type	68	43 (63.2)	25 (36.8)
Mixed type	7	5 (71.4)	2 (28.6)
Differentiation grade
Low and middle	107	68 (63.6)	39 (36.4)	0.744
High	33	22 (66.7)	11 (33.3)
Cancer embolus
Yes	51	29 (56.9)	22 (43.1)	0.165
No	89	61 (68.5)	28 (31.5)
Affect neural
Yes	50	29 (58.0)	21 (42.0)	0.247
No	90	61 (67.8)	29 (32.2)
TNM staging
I	10	10 (100.0)	0 (0.0)	0.000
II	49	44 (89.8)	5 (10.2)
III	81	36 (44.4)	45 (55.6)

LOX: Lysyl oxidase; WHO: Word Health Organization; TNM: Tumor-node-metastasis.